Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX
Other stock markets
 03:23:44 2024-06-05 pm EDT 		5-day change 1st Jan Change
1,009 USD +1.58% Intraday chart for Regeneron Pharmaceuticals, Inc. +4.35% +14.83%
02:30pm Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM
Jun. 04 RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185 MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185
MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK
DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials
CI
Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD
AQ
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee
MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
DJ
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GL
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
AQ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD
CI
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
GL
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
AQ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing
MT
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
PR
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.